Clinical Trial

Laparoscopic Staging for Stage III Gastric Cancer

Study acronym: CGCA202501
Enrolling by Invitation
View on ClinicalTrials.gov →
Summary
This study aims to determine, through a multicenter randomized controlled design, the impact of precision treatment guided by laparoscopic staging on overall survival (OS), surgical conversion rate, and peritoneal metastasis rate in patients with clinical stage III gastric cancer, thereby providing evidence for precision staging and treatment decision-making.
Trial Details
NCT Number NCT07533825
Lead Sponsor Tianjin Medical University Cancer Institute and Hospital
Collaborators: Peking University International Hospital, Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Peking University People's Hospital, First Hospital of China Medical University, The First Hospital of Jilin University, Liaoning Cancer Hospital & Institute, Hebei Medical University Fourth Hospital, Changzhi People's Hospital, Shaanxi Provincial People's Hospital, General Hospital of Ningxia Medical University, Lanzhou University Second Hospital, Qianfoshan Hospital, Shandong Provincial Hospital, Qilu Hospital of Shandong University, Yantai Yuhuangding Hospital, Shanghai Zhongshan Hospital, RenJi Hospital, Fudan University, Anhui Provincial Hospital, The First Affiliated Hospital with Nanjing Medical University, The Affiliated Hospital of Xuzhou Medical University, Zhejiang Cancer Hospital, Second Affiliated Hospital of Soochow University, Tongji Hospital, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Jiangxi Provincial Cancer Hospital, West China Hospital, Guangdong Provincial People's Hospital, Fujian Medical University Union Hospital, Fujian Cancer Hospital, Tang-Du Hospital, Renmin Hospital of Wuhan University
Conditions Gastric Cancer (GC), Gastric Adenocarcinoma
Enrollment 968 participants
Start Date 2025-02-01
Primary Completion 2026-12-31 (estimated)
Study Completion 2029-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-04-16